The 2022 ACC Expert Consensus suggests that statins can be supplemented by other lipid-lowering agents, such as proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), bempedoic acid, or ezetimibe, for further optimizing LDL-C reduction and managing LDL-related ASCVD risk (8). The gene discussed is PCSK9; the disease is atherosclerosis.